🩸 Heparin-Induced Thrombocytopenia (HIT): Complete Review

🩸 Heparin-Induced Thrombocytopenia (HIT): Complete Review

— Test Purpose · CLIA Principle · Interpretation Tips · Related Conditions

Heparin-Induced Thrombocytopenia (HIT) is a serious immune-mediated complication that causes thrombocytopenia and thrombosis after exposure to heparin. Not all decreases in platelet count represent HIT; therefore, confirming the presence of PF4–Heparin IgG antibodies is essential for accurate diagnosis.

This article summarizes the purpose of HIT antibody testing, CLIA methodology, interpretation, limitations, and associated clinical conditions — from a diagnostic medicine perspective.

---

1. What Is HIT?

HIT is classified into two distinct forms:

✔ Type 1 HIT (Non-immune, Benign)

• Occurs within 1–2 days after starting heparin
• Mild thrombocytopenia
• PF4 antibodies negative
• Clinically insignificant
• Platelet count recovers spontaneously

✔ Type 2 HIT (Immune-mediated — true HIT)

• Formation of IgG antibodies against PF4–Heparin complexes
• Antibody–platelet interaction through FcγRIIa → platelet activation + thrombosis
• Causes significant thrombocytopenia and potentially fatal thrombotic events
• Requires urgent treatment

---

2. Purpose of HIT Antibody Testing

HIT testing aims to determine whether immune-mediated HIT is present.

✔ 1) Detect PF4–Heparin IgG antibodies

The key diagnostic marker for immune thrombocytopenia associated with heparin.

✔ 2) Differentiate HIT from other causes of thrombocytopenia

• Sepsis
• DIC
• Postoperative thrombocytopenia
  These are common but require different management compared to HIT.

✔ 3) Determine whether heparin can be continued

• Positive HIT Ab ⇒ Stop UFH/LMWH immediately
• Switch to non-heparin anticoagulants (argatroban, bivalirudin, etc.)

---

3. Test Method: CLIA (Chemiluminescent Immunoassay)

HIT antibody detection is commonly performed using CLIA, an automated, highly sensitive immunoassay.

✔ Principle

1. Magnetic beads coated with PF4–Heparin complexes
2. Patient plasma is incubated → antibodies bind if present
3. Anti-IgG detection antibodies + chemiluminescent substrate added
4. Light emission proportional to antibody concentration

✔ Advantages

• High sensitivity
• Rapid and automated
• Better specificity compared to traditional ELISA

---

4. Specimen Requirements

• Specimen: Plasma
• Tube: Sodium citrate
• Stability: Test immediately or store at 2–8°C
• Interference: Hemolysis, lipemia may affect results

---

5. Reference Range

Result	Interpretation
< 1.0 U/mL	Negative
1.0 – 1.4 U/mL	Equivocal
≥ 1.5 U/mL	Positive

Ranges may vary by test kit or analyzer; follow your institutional reference intervals.

---

6. Clinical Significance — When Is HIT Ab Increased?

Positive Result Suggests:

• Thrombocytopenia occurring 5–14 days after starting heparin
• Immediate thrombocytopenia after re-exposure
• Thrombosis (DVT, PE, arterial clots, prosthetic valve thrombosis)
• Intermediate or high 4T score (≥ 4)

Negative Result Suggests:

• HIT unlikely
• But caution in:
  • Testing too early (≤ 3–4 days after exposure)
  • Immunocompromised patients (delayed antibody production)

---

7. Conditions Associated With HIT & Differential Diagnosis

✔ HIT-Associated Conditions

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Arterial thrombosis
• Skin necrosis
• Widespread thrombosis (“white clot syndrome”)

✔ Conditions to Differentiate

• DIC
• Sepsis
• Postoperative thrombocytopenia
• Drug-induced immune thrombocytopenia
• ITP

---

8. Critical Interpretation Tips (Most Important Section)

✔ 1) Positive antibody ≠ HIT diagnosis

CLIA is sensitive but not highly specific.
Always interpret with clinical probability.

✔ 2) Combine with the 4T score

• Thrombocytopenia
• Timing
• Thrombosis
• oTher causes

4T score < 4 → HIT unlikely → testing often unnecessary.

✔ 3) D-dimer often elevated

Reflects concurrent thrombosis.

✔ 4) Stop heparin immediately if HIT is strongly suspected

Do not wait for test results.

✔ 5) UFH has higher HIT risk than LMWH

Especially in surgical and ICU patients.

FDP Complete Guide – MedLab Insight

---

9. Summary

• HIT is an immune-mediated thrombocytopenia with high thrombotic risk.
• PF4–Heparin IgG antibodies are measured using CLIA.
• Interpretation requires clinical correlation, especially with the 4T score.
• Early recognition and cessation of heparin are critical to prevent fatal events.

---

10. References

1. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation.
2. Cuker A, et al. ASH 2018 Guidelines for Management of HIT. Blood Advances.
3. Greinacher A. CLIA-based assays for HIT antibodies. J Thromb Haemost.
4. UpToDate. Clinical presentation and diagnosis of HIT.
5. CLSI. Laboratory testing for heparin-induced thrombocytopenia.

Clinical presentation and diagnosis of heparin-induced thrombocytopenia – UpToDate